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Abstract 
Background: Bipolar disorder I (BD-I) is defined by episodes of mania, depression, and euthymic 
states. These episodes are among other symptoms characterized by altered reward processing and 
negative symptoms (NS), in particular apathy. However, the neural correlates of these deficits are 
not well understood. 
Methods: We first assessed the severity of negative symptoms in 25 euthymic BD-I patients 
compared to 25 healthy controls (HC) and 27 patients with schizophrenia (SZ). Then, we investigated 
ventral and dorsal striatal activation during reward anticipation in a Monetary Incentive Delayed Task 
and its association with NS.  
Results: In BD-I patients NS were clearly present and the severity of apathy was comparable to SZ 
patients. Apathy scores in the BD-I group but not in the SZ group correlated with sub-syndromal 
depression scores. At the neural level, we found significant ventral and dorsal striatal activation in 
BD-I patients and no group differences with HC or SZ patients. In contrast to patients with SZ, apathy 
did not correlate with striatal activation during reward anticipation. Explorative whole brain analyses 
revealed reduced extra-striatal activation in BD-I patients compared to HC and an association 
between reduced activation of the inferior frontal gyrus and apathy. 
Conclusion: This study found that in BD-I patients apathy is present to an extent comparable to 
schizophrenia, but is more strongly related to sub-syndromal depressive symptoms. The findings 
support the view of different pathophysiological mechanisms underlying apathy in the two disorders 
and suggest that extra-striatal dysfunction may contribute to impaired reward processing and apathy 
in BD-I. 
 
Key words: bipolar disorder, euthymic, apathy, diminished expression, fMRI, monetary incentive 
delay task, negative symptoms, reward anticipation, striatum, transdiagnostic   
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Introduction 
Bipolar disorder I (BD-I) is a severe neuropsychiatric illness that causes extensive individual morbidity 
and socioeconomic burden (Vos et al., 2012). Clinically, the disorder is defined by the occurrence of 
at least one manic episode and often includes recurrent states of depressive, manic, mixed and 
euthymic episodes (Association, 2013). It is increasingly becoming evident that processing of 
motivation and reward are affected in all of these states (Ashok et al., 2017). This is supported by 
recent findings showing a transdiagnostic dopamine dysfunction spanning from bipolar disorder to 
schizophrenia (Jauhar et al., 2017). In order to understand the relationship between dysfunctional 
motivational processes and clinical disease manifestations within but also between different 
diagnostic entities, valid dimensional psychopathological constructs are essential (Cuthbert and Insel, 
2013).  
Negative symptoms (NS) have been proposed as such a construct (Strauss et al., 2016). Originally 
considered as a hallmark symptom complex of schizophrenia (Kraepelin, 1921), it has become 
evident that NS also occur outside of the schizophrenia-spectrum (Strauss and Cohen, 2017). A 
recent study reported that NS can indeed be measured in BD-I patients (Strauss et al., 2016). NS can 
be grouped into a motivational dimension (hereafter referred to as apathy) containing anhedonia, 
avolition and asociality, and a diminished expression dimension, which includes blunted affect and 
alogia (Blanchard and Cohen, 2006, Strauss et al., 2013). Critically, increasing evidence from several 
fields suggests that the two dimensions are caused by different neurobiological and behavioural 
mechanisms (Caravaggio et al., 2018, Cathomas et al., 2015, Hager et al., 2015, Hartmann et al., 
2015, Wolf et al., 2014). This differentiation might therefore be critical for the development of 
effective treatment (Galderisi et al., 2018, Kaiser et al., 2017). With respect to the relevance of NS in 
BD several studies have reported elevated NS scores even in euthymic patients (Hawkins et al., 1997, 
Mancuso et al., 2015, Strauss et al., 2016), which are strongly associated with functional impairments 
(Atre-Vaidya et al., 1998, Samalin et al., 2016, Serafini et al., 2018). Studies comparing the severity of 
negative symptoms between SZ and BD yield mixed results (Strauss and Cohen, 2017, Tso et al., 
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2014) but suggest that NS might be more stable and trait like in SZ. With respect to the two negative 
symptom dimensions a recent study found that BD patients only differed from SZ patients on the 
diminished expression dimension but showed similar severity of apathy (Strauss et al., 2016). 
Furthermore, several studies have reported residual anhedonic symptoms in euthymic BD patients, 
which were comparable to SZ patients (Di Nicola et al., 2013, Tso et al., 2014) and relevant for 
impaired reward learning (Pizzagalli et al., 2008). Although comparable in trait anhedonia, SZ patients 
showed more severe total negative symptoms, lower experience of pleasure and lower behavioral 
activation (Tso et al., 2014). 
It is well established that striatal dysfunction during reward anticipation plays an important role in 
the pathophysiology of NS in patients with schizophrenia (SZ) (Heinz and Schlagenhauf, 2010, Nielsen 
et al., 2018, Radua et al., 2015). Recent studies suggest a specific link between reduced ventral (VS) 
and dorsal striatal (DS) activity and apathy (Kirschner et al., 2016b, Mucci et al., 2015, Simon et al., 
2010, Stepien et al., 2018, Wolf et al., 2014). In contrast, results regarding reward anticipation in 
euthymic BD patients are conflicting, with studies showing both increased (Mason et al., 2014, 
Nusslock et al., 2012) and unaltered (Caseras et al., 2013, Dutra et al., 2015) VS activity compared to 
healthy controls (HC). To our knowledge the association between NS and striatal dysfunction has not 
been investigated in patients with BD-I. A transdiagnostic approach taking advantage of the current 
findings from schizophrenia research provides a unique opportunity to elucidate the neural 
substrates of motivational deficits in BD. Furthermore, given that only recently extra-striatal 
prefrontal correlates of apathy have been observed (Dowd et al., 2016, Wang et al., 2016), this 
transdiagnostic approach allows the comparison of potential contributions of extra-striatal 
dysfunction to the formation of apathy in BD and SZ. 
The aims of the present study therefore were 1) to explore, on a psychopathological level, the 
association between apathy and other symptom dimensions in BD-I patients currently in an euthymic 
state compared to patients with SZ (Kirschner et al., 2016b), 2) to investigate whether euthymic BD-I 
patients show impaired VS or DS activity during reward anticipation during a variant of the Monetary 
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Incentive Delay (MID) task, 3) to compare BD-I patients to patients with SZ regarding the association 
between VS or DS activity during reward anticipation and the two negative symptom domains apathy 
and diminished expression and 4) to study extra-striatal differences between BD-I patients and HC 
using an explorative whole brain analysis approach.  
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Material and Methods 
Participants 
25 participants with a diagnosis of BD-I and 27 patients with a diagnosis of schizophrenia (Kirschner 
et al., 2016b) were recruited from in- and outpatient units of the Psychiatric Hospital of the 
University of Zurich, Switzerland and affiliated institutions. 25 HC, all currently employed, were 
recruited from the general community. For all participants the inclusion criterion for age was 18 to 55 
years. Regarding the recruitment of euthymic BD-I patients, we included 18 patients from outpatient 
units and 7 patients from inpatient units, which were at the end of their hospitalization. The data 
from SZ patients (11 outpatients and 16 inpatients) and HC rely on our previously published study 
(Kirschner et al., 2016b).  
All patients had a stable medication for at least 14 days and a dose of lorazepam not exceeding 1mg 
daily. Using the structured Mini-International Neuropsychiatric Interview for DSM-IV (Ackenheil et 
al., 1999), we A) confirmed the diagnosis of BD-I or schizophrenia, B) excluded patients with a 
current manic, hypomanic or major depressive episode, C) excluded patients with a history of 
schizoaffective disorder, and D) excluded patients with any other DSM-IV Axis I disorder. Healthy 
controls were screened for neuropsychiatric disorders using the structured Mini-International 
Neuropsychiatric Interview to ensure that they had no previous or present psychiatric illnesses. All 
participants were required to have a normal physical and neurologic status (including the assessment 
of extrapyramidal side effects, i.e. a total score ≤2 on the Modified Simpson-Angus Scale [MSAS] 
(Simpson and Angus, 1970) and no history of major head injury or neurological disorder. Patients 
with BD-I were clinically euthymic and on a stable medication for at least two weeks before the 
study. None of the patients with BD-I showed more than sub-syndromal depressive symptoms 
(Hamilton Depression Rating Scale, HAMD 17 Score < 17), as defined by the International Society for 
Bipolar Disorder (ISBD) Task Force (Tohen et al. 2009). The absence of manic symptoms was 
confirmed with the Young Mania Rating Scale (Young et al., 1978) (mean= 0.4, SD = 0.91, min = 0, 
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max = 4). The study was approved by the local ethics committee of the canton of Zurich and all 
participants provided written informed consent.  
Clinical and neuropsychological assessment 
NS were assessed using the Brief Negative Symptom Scale (Kirkpatrick et al., 2011) to answer all 
research questions in the present study. For comparison with earlier studies, additional assessment 
of NS using the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen NC. Scale for the 
Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983) can be found in 
the Supplementary Results. Apathy was defined based on the BNSS subscales anhedonia (items 1-3), 
asociality (items 5, 6) and avolition (items 7, 8) and diminished expression was defined as the sum of 
the BNSS subscales blunted affect (items 9-11) and alogia (items 12, 13) (Kirkpatrick et al., 2011, 
Mucci et al., 2015). Please note, that the BNSS total score also includes the BNSS distress item, which 
was not included in one of the two factors (Kirkpatrick et al., 2011, Mucci et al., 2015). 
 Additional psychopathological assessment included the Hamilton Depression Rating Scale 21 
(Hamilton, 1967) and Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1990) to 
assess depressive symptoms. The CDSS has also been validated for patients with major depressive 
disorders (Micoulaud-Franchi et al., 2018) and has been suggested as transdiagnostic tool to assess 
subclinical depressive symptoms across BD-I patients and SZ patients. The Global Assessment of 
Functioning Scale (GAF) (Frances et al., 1994) and Personal and Social Performance Scale (PSP) (Juckel 
et al., 2008) were used to assess global level of functioning and the Positive and Negative Syndrome 
Scale (PANSS) (Kay et al., 1989) was used to assess all psychotic symptom dimensions. The PANSS 
factor scores were calculated according to the five-factor model of Wallwork et al. (Wallwork et al., 
2012). Since the different factor scores do not include all the PANSS items, sums of the subscales do 
not add up to the total PANSS score. All participants performed a comprehensive neuropsychological 
test battery, which has been used in previous studies (Hager et al., 2015, Hartmann et al., 2015) 
(Supplementary Methods).  
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MID task 
We employed a variant of the MID (Knutson et al., 2000) with stimuli based on the Cued-
Reinforcement Reaction Time Task (Cools et al., 2005). This modified version was originally 
developed by Simon and colleagues (Simon et al., 2015) and used in previous studies to investigate 
reward anticipation (Kirschner et al., 2016b, Kirschner et al., 2018, Simon et al., 2015). In this variant, 
reward amount was directly determined by the individual response time of each participant (Fig S2). 
This adaptation allowed us to investigate the motivational properties of reward anticipation in the 
presence of strong action-outcome contingencies. Briefly, before starting the experiment 
participants were informed that they would receive all the money won during the two experimental 
sessions. At the beginning of each trial, one of three different cues was presented for 0.75 s. The cue 
indicated the maximum amount participants could gain (i.e., 2 Swiss francs (CHF), 0.40 CHF, or 0 CHF; 
1 CHF = $1.03 US). After a delay of 2.5–3 s, participants had to identify an outlier from 3 presented 
circles and press a button as fast as possible. Immediately after the button press, participants were 
notified of the money they had won (duration of feedback 2 s) (Fig. S1). Error trials were defined as 
trials with an incorrect or late response (after 1 s). In all other trials, we calculated the pay-out 
structure for each trial on the basis of the response times of the previous 15 individual trials (Fig. S2). 
Therefore, the amount of money won depended on the response time in the current trial in relation 
to the response time in the previous 15 trials. The maximum amount of money to be won was 50 
CHF. Every participant performed two training runs, one outside and one inside the scanner. 
Excluding the training sessions, the experiment included two runs with 36 trials of about 10 s each. 
The inter-trial interval (ITI) was jittered from 1 to 9 s with a mean of 3.5 s to enhance statistical 
power. In total, 1 run lasted about 6 min.  
Functional image acquisition 
We used the same protocol as in our previous studies (Kirschner et al., 2016a, Kirschner et al., 
2016b), which is described in the Supplementary Methods. 
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Data analyses 
Data (demographic, clinical, neuropsychological and behavioural) were analysed using SPSS (version 
23, SPSS Inc.) and test for normal distribution was applied for all data. Group differences in socio-
demographic and neuropsychological characteristics were investigated using 2-sample t tests for 
continuous and χ2 tests for categorical data. For non-normally distributed data, Mann–Whitney U 
tests were applied. The association symptom dimensions were investigated using bivariate Spearman 
correlations (r
s
). In particular, apathy was correlated with potential secondary sources for NS 
including depressive symptoms, positive symptoms and antipsychotic dose equivalents. FMRI data 
were analysed using SPM8 (revision 5236, 04-Feb-2013) (Statistical Parametric Mapping, Wellcome 
Trust Centre for Neuroimaging, London, UK). The statistical tests were selected for separate 
comparisons of BD-I patients with HC or SZ, excluding the previously reported comparison of HC with 
SZ (Kirschner et al., 2016b).  
Behavioural data analyses 
The main behavioural outcome measure was response time (RT), defined as the time between target 
presentation and pressing the correct button. We conducted a 2-way repeated measures analysis of 
variance (ANOVA) with RT as dependent variable, group as between-subjects factor and reward 
condition (neutral, low, high) as within-subject factor. We performed the Mauchly test for the 
assumption of sphericity and in case of violations report Greenhouse–Geisser–corrected degrees of 
freedom. Bonferroni-corrected pairwise comparisons were calculated as post hoc tests for significant 
main effects. We performed correlation analysis between negative symptom factors and reward-
related speeding. Reward-related speeding was calculated by subtracting the RT during the neutral 
condition (CHF 0) from the RT during the high reward condition (CHF 2.0). One BD-I subject was 
excluded only from the behavioural analysis due to corrupted data files. To account for multiple 
comparisons (group comparison of BD-I patients with HC and patients with SZ separately), we 
considered findings at p<0.025 as significant. 
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Image pre-processing 
The Image pre-processing followed the same protocol as in our previous studies (Kirschner et al., 
2016a, Kirschner et al., 2016b) and is outlined in the Supplementary Methods.  
First- and second-level image analyses 
A general linear model (GLM) approach was applied to assess data in an event-related design at the 
first level. For the three different reward anticipation phases, separate regressors were included: 
anticipation of no reward (CHF 0), anticipation of low reward (CHF 0.40) and anticipation of high 
reward (CHF 2.0). For the outcome phases, regressor for each condition (three basic regressors) was 
included. Additionally, for the low and high reward conditions the two outcome regressors were 
parametrically modulated by the actual outcome amount of each trial. Target presentation (one 
regressor) and anticipation, target and outcome phase in error trials (three regressors) were 
modelled as regressors of no interest. In total, the first-level model included 12 regressors. The 
canonical hemodynamic response function was used for convolving all explanatory variables. For 
reward anticipation the contrast anticipation of high reward (CHF 2.0) versus anticipation of no 
reward (CHF 0) was calculated. At the second-level analysis, individual contrast images of all 
participants were included in a random-effects model. Within-group activation was calculated using a 
1-sample t test and between-group activation using a 2-sample t test. For all whole brain analysis the 
statistical threshold was set to p<0.05, whole-brain cluster-level family-wise error (FWE) rate 
corrected for multiple comparisons with a cluster-defining voxel-level threshold of p<0.001 
uncorrected. 
Region of interest image analysis 
The VS and DS were defined as regions of interest (ROIs) during anticipation of reward. We derived 
VS coordinates (Montreal Neurological Institute [MNI]) from a meta-analysis (Knutson and Greer, 
2008) (left: x= -12, y= 10, z= -2; right: x= 10, y= 8, z= 0; 9mm sphere in one single VS ROI). DS 
coordinates were derived from a previously published fMRI data, indicating DS activation in response 
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to the MID task (left: x=-9, y=3, z=15; right: x=9, y=3, z=15; 9mm sphere in one single DS ROI) (Yip et 
al., 2015). This ROI approach was adapted from (Yip et al., 2015) and has been used in our previous 
studies (Kirschner et al., 2016a, Kirschner et al., 2016b). The ROIs were constructed with the Wake 
Forest University Toolbox implemented in SPM8 (Maldjian et al., 2003). The statistical thresholds at 
the voxel level were set to a family-wise error (FWE) corrected threshold for multiple comparison of 
p = 0.05 in each ROI. Mean percent signal changes were extracted for all voxels in the VS and DS 
using the REX toolbox (http://web.mit.edu/swg/software.htm). In other words, extraction and 
average calculation was not restricted to the significant voxels but to all voxels of the ROIs. In 
addition, we performed an extra-striatal ROI analysis in the prefrontal cortex, which was based on 
previous findings showing an association between a behavioural measure of apathy and reduced 
inferior frontal gyrus (IFG) activation (Kluge et al., 2018). Structural masks of the left and right IFG 
were derived from the IBASPM 71 atlas implemented in the Wake Forest University Toolbox in SPM8 
(Maldjian et al. 2003). 
Correlation analysis 
The main hypothesis was tested by calculating bivariate Spearman correlations (r
s
) between negative 
symptoms (apathy and diminished expression) and percent signal change in the VS and DS. Finally, 
the Steiger test for dependent correlation coefficients was performed to test for potential 
differences between these correlations (Steiger, 1980). 
Results 
Sample characteristics 
Participant characteristics, clinical data and group comparisons are summarized in Table 1. Patients 
with BD-I had a significant higher average number of education years compared to HC and SZ 
patients. Patients in the BD-I group were older than SZ patients and were characterized by a longer 
duration of illness compared to the SZ group. On both the Global Assessment of Functioning (t = -
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2.613, p = 0.012) and the Personal and Social Performance Scale (t = -2.163, p = 0.036) BD-I patients 
scored higher, indicating a higher level of functioning compared to patients with SZ. In the BD group 
18 out of 25 patients were treated with atypical antipsychotics, 18 patients received mood stabilizer 
and 7 patients antidepressants. All patients with SZ received atypical antipsychotics. Mean 
chlorpromazine equivalents were higher in patients with SZ compared to BD-I patients (BD-I: 185.99 
± 259.8, SZ: 508.01 ± 369.2; U = 133, p < 0.001). None of the patients received typical antipsychotics.  
Psychopathological data 
To address our first aim, we compared the severity of NS in BD-I with SZ patients (Fig. 1 and Table 1 
for statistics). Whereas the two groups did not differ in BNSS apathy (Fig. 1A), BD-I patients scored 
significantly lower on the BNSS expression subscale (Fig. 1B). Moreover, we observed a trend that 
BD-I patients have less total BNSS scores compared to SZ patients. 
BD-I patients showed higher CDSS scores than SZ patients (Fig. 1C). There was a significant 
correlation between BNSS apathy and CDSS in BD-I (Fig. 1D) but not in patients with schizophrenia 
(Fig. 1E). There was no significant correlation between BNSS diminished expression and CDSS in 
either group (BD-I: r
s
 = 0.268, p = 0.195; SZ: r
s
 = 0.174, p = 0.385). Given the significant correlation 
between apathy and subclinical depressive symptoms, we performed additional correlation analyses 
with the three subdomains anhedonia, avolition and asociality of the BNSS apathy factor. In BD, all 
three subdomains were correlated with depressive symptoms (anhedonia: rs = 0.599, p = 0.002; 
avolition: rs = 0.418, p =0.038; asociality: rs = 0.397 p = 0.049). Although these findings suggest a 
stronger association between anhedonia and depression, we did not observe a significant difference 
compared to the correlation between avolition and depression (Z = 1.60, p = 0.109) and the 
correlation between asociality and depression (Z = 1.464, p = 0.143). Additionally, the BNSS items 
comprising blunted affect did not correlate with the CDSS score in BD I (r
s
 = 0.294, p = 0.154) and SZ 
patients (r
s
 = 0.163, p = 0.418). In sum, these analyses suggest that in BD-I patients, subclinical 
depressive symptoms were associated with all three subdomains of the apathy factor. 
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Taken together, these findings revealed that BD-I patients have similar levels of apathy but lower 
levels of diminished expression compared to SZ patients. Interestingly, apathy was correlated with 
sub-syndromal depressive symptoms in BD-I patients but not in patients with SZ.  
BD-I patients had lower scores on the PANSS positive symptom subscale than SZ patients. However, 
there was no correlation of positive symptoms with BNSS apathy in either of the groups (BD-I: r
s
 = - 
0.019, p = 0.928; SZ: r
s
 = -0.136, p = 0.500). Regarding antipsychotic medication, chlorpromazine 
equivalents were higher in patients with SZ compared to BD-I patients (BD-I: 185.99 ± 259.8, SZ: 
508.01 ± 369.2; U = 133, p < 0.001). However, there was no correlation with BNSS apathy in either of 
the groups (BD-I: r
s
 = 0.207, p = 0.320; SZ: r
s
 = -0.047, p = 0.816). Thus, no evidence for a contribution 
of positive symptoms or antipsychotic medication to the observed apathy symptoms was found.  
Behavioural data 
Comparison between BD-I patients and HC 
The repeated-measures ANOVA with reward condition as within-subject factor and group affiliation 
as between-subject (BD-I patients and HC) factor revealed a significant main effect of reward 
(F(1.5,70) = 67.661, p < 0.001) but no significant effect of group (F(1, 47) = 2.196, p = 0.15) or group x 
reward interaction (F(1.5, 70) = 2.117, p = 0.14). Bonferroni post-hoc pairwise comparison of 
response times revealed significant differences between all reward conditions (all p < 0.001; no 
reward < low reward < high reward). These results indicate intact reward-related speeding in HC and 
BD-I. Furthermore, neither BNSS apathy nor BNSS expression correlated significantly with reward-
related speeding (BNSS apathy: r = -0.062, p = 0.774; BNSS expression: r = 0.018, p = 0.933). Finally, 
we did not find group differences in total error rates (BD-I: 5.4 ± 3.6, HC: 5.7 ± 4.0; U = 293.5, p = 
0.896) or total money gain (BD-I: 39.5 ± 4.5, HC: 38.9 ± 5.2; U = 274, p = 0.603) (Table S1).  
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Comparison between BD-I patients and SZ patients 
We repeated the same analysis to compare the BD-I patients with the previously published sample of 
chronic SZ patients (Kirschner et al., 2016b) . The repeated-measures ANOVA with reward condition 
as within-subject factor and group affiliation as between-subject factor (BD-I and SZ patients) 
revealed a significant main effect of reward (F(1.4, 67) = 39.376, p < 0.001) but no significant effect of 
group (F(1, 49) = 0.049, p = 0.83) or group x reward interaction effect was observed (F(1.4, 67) = 
2.907, p = 0.08) (Table S1). None of the measures for task performance (response time, error rate, 
total gain) showed a significant correlation with IQ (estimated with the MWT) (Table S2). 
fMRI data 
Group comparison of VS and DS activation between BD-I patients and HC 
A voxel-wise whole-brain analysis of the reward anticipation contrast in the combined sample of BD-I 
patients and HC revealed strong task-related activation in reward coding regions including the VS and 
DS (Table S6, Figure 2).  
To address the second aim of the study (relation of group to VS and DS activity), we compared the 
mean contrast signal from our a priori defined VS and DS ROI between HC and patients with BD-I 
(Figure 3A, C). There were no significant group differences in neural activation during reward 
anticipation in the VS (t = 0.412, p = 0.682) or DS (t = 1.09, p = 0.279). Thus, the VS and DS showed 
increased activity related to reward anticipation irrespective of group membership. Furthermore, in 
an explorative analysis we did not observe group differences in the low reward – no reward 
anticipation contrast and high reward – low reward anticipation contrast (Table S3).  
Group comparison of VS and DS activation between BD-I patients and SZ 
In a next step we compared the mean contrast signal of the VS and DS ROI between BD-I patients and 
the previously published sample of chronic SZ patients (Kirschner et al., 2016b). There were no 
significant group differences in neural activation during reward anticipation in the VS (t = 0.93, p = 
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0.357) or DS (t = 0.267, p = 0.79). Thus, VS and DS activations during reward anticipation did not 
differ significantly between BD-I patients and chronic SZ patients.  
Correlation analysis between reward anticipation and negative symptom domains 
The third aim of the study was to investigate the association between the two negative symptom 
dimensions apathy and diminished expression and the mean contrast signal in our a priori ROIs of the 
VS and DS. Neither VS activity nor DS activity during reward anticipation were associated with one of 
the two negative symptom dimensions apathy or diminished expression (VS: apathy r
s
 = - 0.002, 
diminished expression r
s
 = - 0.058; DS: apathy r
s
 = 0.189, diminished expression r
s
 = 0.236, all p>.05) 
(Figure 3B, D). In sum, in patients with BD-I neither apathy nor diminished expression showed any 
association with reward anticipation in the striatum.  
In a further analysis we investigated the potential correlation between depressive symptoms (CDSS 
Total score) and reward anticipation in the VS and DS. Again, we did not find any association 
between symptom expression and VS and DS activity (VS: r
s
 = 0.136, p = 0.515; DS: r
s
 = 0.145, p = 
0.490). Furthermore, neither in BD-I patients nor in patients with SZ antipsychotic medication dose 
correlated with striatal activation during reward anticipation (SZ, VS: r
s
 = 0.128, p = 0.525, DS: r
s
 = 
0.045, p = 0.824; BD-I, VS: r
s
 = 0.086, p =0.684, DS: r
s
 = -0.052, p = 0.804). Additionally, VS and DS 
activation during reward anticipation were not associated with functioning or education (Table S5). 
In the next step, we compared the correlation between apathy and VS activity in BD-I patients with 
the previous published negative correlation between apathy and VS activity in schizophrenia 
patients. Using Fisher r-to-z transformation we found a trend level significance (Z = 1.72, p = 0.085 
two-tailed) for the differences between the two correlation coefficients suggesting that the 
association between apathy and ventral striatal activation was stronger in patients with 
schizophrenia than in patients with BD-I. Finally, we conducted explorative correlation analyses for 
the low reward – no reward anticipation contrast and high reward – low reward anticipation 
contrast, which revealed no significant correlation with apathy (Table S4). 
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Extra-striatal dysfunction during reward anticipation 
The fourth aim of the study was to identify potential extra-striatal prefrontal group differences in 
brain activity during reward anticipation. In our a priori IFG ROI, no group differences were observed 
comparing BD-I patients with HC and SZ patients. Furthermore, SZ patients did not differ from HC. 
Additional explorative whole brain analysis in BD-I patients revealed reduced activation during 
reward anticipation in the fusiform gyrus, lingual gyrus and precuneus compared to HC (Table S7).  
In a next step, we aimed to identify potential associations between apathy and reduced activation in 
extra-striatal regions. Based on previous findings from our own group, we expected a negative 
association between apathy and IFG activation. Please, note that the main effect of high reward 
anticipation versus reward anticipation across the complete sample revealed activity in the right and 
left IFG supporting the relevance of this region in reward anticipation. In BD-I patients, we found a 
significant negative association between right IFG activation and apathy (56, 27, 9, cluster size = 41, t 
= 5.05, p=.034, peak-level FWE <0.05 corrected) (Fig 4). No association was observed in the left IFG. 
Please note that after Bonferroni correction for the number of ROIs this result was only at trend-level 
significance (p=.068). A secondary linear regression model with the log-transformed CDSS scores 
revealed no significant association between sub-syndromal depressive symptoms and reduced IFG 
activation. To test whether BD-I patients and SZ patients share the same apathy related IFG 
hypoactivation, we repeated the linear regression with apathy and IFG activation during reward 
anticipation in patients with SZ. In contrast to BD-I patients, we did not observe an association 
between apathy and reduced IFG activation in patients with SZ. 
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Discussion 
The present study investigated apathy and diminished expression in euthymic BD-I patients and its 
association with VS and DS activation during reward anticipation in a variant of the MID task. In 
euthymic BD-I patients, clinically measured severity of apathy was similar to patients with 
schizophrenia (Kirschner et al., 2016b). However, BD-I patients showed less emotional expressivity 
deficits than patients with SZ. On the neural level, apathy was not associated with VS and DS activity 
during reward anticipation but showed an association with reduced prefrontal activation in the IFG.  
It has recently been suggested that NS constitute a valid transdiagnostic psychopathological 
construct (Strauss et al., 2016). In the present study, we confirm that NS can be assessed in euthymic 
BD-I patients and that the overall severity of both total BNSS and BNSS apathy is not different 
compared to a recently published study with schizophrenia patients (Kirschner et al., 2016b). In 
contrast, BD-I patients scored less on the BNSS expression subscale than schizophrenia patients. 
Findings of similar scores on the BNSS apathy subscale but differences in BNSS expression are in line 
with a recent study by Strauss and colleagues (Strauss et al., 2016). Although not fulfilling the criteria 
for a depressive episode, BD-I patients showed more depressive symptoms compared to SZ patients 
and these correlated significantly with BNSS apathy in the BD-I but not in the SZ group. Interestingly 
in euthymic BD-I patients, subclinical depressive symptoms were related to all three subdomains of 
the BNSS apathy factor: anhedonia, avolition and asociality. These findings suggest that when 
exploring NS in BD it might be difficult to differentiate symptoms such as anhedonia from other 
depressive symptoms (here assessed with the CDSS). This overlap and its potential impact on 
underlying neurobiological mechanism should be taken into account when investigating NS and 
depression in a transdiagnostic way. Furthermore, it is well known that BD-I patients in the euthymic 
state as determined by diagnostic criteria and structured interviews, display a broad range of 
neuropsychological and psychopathological impairments, including sub-syndromal depressive 
symptoms (Bourne et al., 2013, Roux et al., 2017). These residual depressive symptoms – in contrast 
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to residual hypomanic symptoms – are an important predictor of functional outcome and quality of 
life (Bonnin et al., 2010, Dias et al., 2008).  
When interpreting the results of the present study, it is therefore important to take into account the 
concept of secondary negative symptoms: Whereas primary negative symptoms are defined by being 
inherent to the disorder, secondary negative symptoms are thought to have different underlying 
sources such as depressive symptoms, productive psychotic features or medication (Kirkpatrick, 
2014, Kirschner et al., 2017). Our data clearly show that in euthymic patients with bipolar disorder 
motivational negative symptoms are at least in part secondary to sub-syndromal depressive 
symptoms. In contrast, we found no evidence for a contribution of other secondary sources of 
negative symptoms such as positive symptoms or medication side-effects. Taken together, the 
psychopathological findings of our study suggest that whereas NS can indeed be assessed as a 
transdiagnostic construct, the specific characteristics of the different subdomains are likely to differ 
between traditional categorical disease entities, emphasizing the importance of a detailed 
psychopathological assessment. 
While the clinically measured severity of apathy in BD-1 patients was comparable to that of patients 
with schizophrenia, the specific association of apathy to sub-syndromal depressive symptoms in BD-I 
patients but not SZ patients, suggest different underlying neural mechanisms during reward 
anticipation: In contrast to the growing evidence that apathy is associated with reduced striatal 
activity in schizophrenia (Kirschner et al., 2016b, Mucci et al., 2015, Wolf et al., 2014), this 
association was not observed in patients with euthymic BD-I. In addition, in line with previous studies 
in euthymic BD patients (Caseras et al., 2013, Yip et al., 2015) we did not observe an association 
between striatal activity and sub-syndromal depressive symptoms. Though speculative, one 
explanation for these divergent findings might be that primary and secondary negative symptoms 
have divergent neural correlates. While apathy, as a primary negative symptom, is associated with 
striatal dysfunction, apathy secondary to sub-syndromal depressive symptoms may be related to 
extra-striatal mechanisms. Our findings suggest that apathy in patients with BD-I might be more 
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strongly related to cognitive processes relevant for action initiation and execution as reflected by 
prefrontal cortex activation (Barch and Dowd, 2010). Critically, the observed association between 
apathy and reduced IFG activation during reward anticipation is in line with previous results showing 
reduced IFG activation in bipolar depression (Redlich et al., 2015). The relevance of prefrontal activity 
in euthymic and sub-syndromal depressive BD-I patients is underpinned by research reporting 
reduced top-down control of anteroventral prefrontal cortex on VS activity during reward processing 
(Trost et al., 2014). Nevertheless, our findings have to be interpreted with caution given that only 
apathy but not depression was associated with reduced prefrontal cortex activation in the present 
study. In addition, some studies in bipolar depression, unipolar depression and schizophrenia have 
shown a correlation between depressive symptom scores and reduced striatal activity (Arrondo et 
al., 2015, Hagele et al., 2015, Satterthwaite et al., 2015). Taken together, the potentially shared and 
distinct neural substrates of primary apathy and secondary apathy due to depression still have to be 
elucidated.  
An additional explanation for these divergent findings might be the greater heterogeneity of neural 
activation during reward anticipation in different stages and subtypes of BD. While the meta-analysis 
of Radua and colleagues (Radua et al., 2015) demonstrated that there is consistent evidence for 
reduced striatal activation during reward anticipation in SZ, the findings in BD are still inconclusive 
(Ashok et al., 2017). Recently, Caseras and colleagues reported increased bilateral VS activity in BD-II 
patients, but no differences in BD-I patients compared to HC (Caseras et al., 2013). This is in line with 
our observation of comparable activation during reward activation in euthymic BD-I patients and HC. 
However, a recent study by Yip et al. showed that during reward anticipation, unmedicated BD-II 
patients had decreased DS but not VS activity (Yip et al., 2015). Here, similar to the literature on 
schizophrenia, which reported opposing results in unmedicated patients and patients treated with 
atypical antipsychotics (Nielsen et al., 2012, Schlagenhauf et al., 2008), the divergent findings might 
be due to differences in medication between the present study (medicated) and the previous report 
from Yip and colleagues (unmedicated) (Yip et al., 2015). In sum, these findings point towards 
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different mechanisms underlying motivational deficits between different stages and subtypes of BD. 
Of note, the explorative whole brain analyses of our study revealed reduced extra-striatal activation 
in fusiform gyrus, lingual gyrus and precuneus in BD-I compared to HC. These results replicated 
previous findings in BD-II patients (Yip et al., 2015) and suggest that temporal, occipital and parietal 
regions involved in reward processing (Sescousse et al., 2013) are impaired in euthymic BD-I patients.  
Limitations and future directions 
There are several limitations to the present study: First, the sample size is only moderate and 
although we made an effort to recruit a homogeneous sample regarding the current disease stage, it 
is challenging to minimize variance in number of past depressive/manic episodes and duration of 
illness in chronic BD-I patients. These characteristics could mask specific mechanisms underlying 
various stages of the disorder. In particular, we did not use a conservative definition of euthymia 
(Samalin et al., 2016), but allowed sub-syndromal depressive symptoms according to the definition of 
the ISBD Task Force (Tohen et al., 2009). In order to elucidate specific neural correlates of different 
stages in BD, future neuroimaging studies should take advantage of precise recommendations to 
overcome the high variability in clinical criteria and duration for euthymia used in previous research 
(Robinson et al., 2006, Samalin et al., 2016, Tohen et al., 2009). Furthermore, the present patient 
sample consists of medicated patients and does not take into account possible confounding effects 
of psychotropic drugs (Phillips et al., 2008) since subgroups were too small to conduct post hoc 
comparisons between different drug classes. Third, the lack of specific measures for anhedonia other 
than the BNSS may have hampered the ability to identify distinct correlates for subdomains of 
apathy. Therefore, further studies should investigate detailed psychopathological characteristics 
including specific measures for anhedonia and motivational deficits during different episodes of the 
disorder. Especially, within-subject designs investigating different disease stages on an individual 
level could reveal important insights into the variability of the underlying neural mechanisms. 
Though speculative, understanding these processes could be an important step towards the 
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development of targeted treatment interventions that address the oftentimes so burdensome 
switching between the different episodes of BD-I. 
 
Conclusion 
The present study indicates that on a psychopathological level apathy is present in euthymic BD-I 
patients comparable to patients with schizophrenia but appear to be related to sub-syndromal 
depressive symptoms. This highlights the relevance of detailed clinical assessments of other 
symptom dimensions in transdiagnostic studies of apathy. The lack of convergent neural correlates of 
apathy in the striatum and the association of apathy with extra-striatal dysfunction in BD-I patients 
suggests divergent neurobiological mechanisms of apathy in BD-I patients compared to SZ patients. 
Thus, this transdiagnostic approach contributes to the empirical differentiation of shared and 
divergent pathophysiological mechanisms of apathy across psychiatric disorders. Taken together, 
these findings strengthen the notion to investigate motivational deficits in a dimensional approach as 
conzeptualized in the Research Domain Criteria (Cuthbert and Insel, 2010) in order to foster progress 
for new treatments (Strauss & Cohen 2017; Husain & Roiser 2018). 
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Table 1. Sample Characteristics 
 BD-I (N=25) SZ (n=27) HC (n=25) BD-I vs. HC BD-I vs. SZ 
Age (yr) 37.3 ± 9.1 31.9 ± 7.4 33.1 ± 9.7 t = -1.579, 
p = 0.121 
t= -2.343, 
p = 0.023 
Sex (male/female) 16/9 18/9 16/9 χ
2
 = 0, 
p = 1 
χ
2 
=0.041, 
p = 0.840 
Education (yr) 14.6 ± 3.5 12.2 ± 3.1 12.4 ± 3.6 U = 194.5, 
p = 0.021 
U = 190.5, 
p = 0.007 
Duration of illness (yr) 15.4 ± 9.0 9.2 ± 6.6   U = 197.5, 
p = 0.01 
Age of onset (yr) 21.9 ± 5.7 22.7 ± 6.0   t = 0.472, 
p = 0.639 
Handedness (r/l) 24/1 24/3 22/3 χ
2
 = 1.087, 
p = 0.297 
χ
2
 = 0.924, 
p = 0.336 
Psychopathology 
     
BNSS score      
  Apathy (motivation and pleasure) 13.0 ± 8.3 14.8 ± 6.9   t = 0.839, 
p = 0.406 
  Avolition 3.4 ± 2.5 4.5 ± 2.2   t = 0.061 
p =  0.952 
  Anhedonia 6.5 ± 4.5 6.4 ± 4.5   t = -1.669 
p = 0.101 
  Asociality 3.1 ± 2.2 3.8 ± 2.3   t = -1.179 
p = 0.244 
  Diminished expression 4.32 ± 4.5 8.4 ± 7.2   U = 224, p = 0.037 
  Blunted Affect 3.4 ± 3.2 5.9 ± 4.9   U = 239.5 
p = 0.071 
  Alogia 0.92 ± 1.5 2.5 ± 2.9   U = 233.5 
p = 0.04 
  Distress 0.72 ± 1.2 0.8 ± 1.5   U = 336.5 
p = 0.983 
  BNSS total score  18.1 ± 12.1 24.6 ± 12.4   U = 238, 
p = 0.068 
PANSS score      
  Positive (P1, P3, P5, G9) 4.4 ± 1.0 6.6 ± 2.5   U = 149.5, 
p < 0.0001 
  Negative (N1, N2, N3, N4, N6, G7) 10.3 ± 3.7 13.6 ± 5.2   U = 213,  
p = 0.022 
  Disorganized (P2, G5, N11) 3.6 ± 1 4.5 ± 2.2   U = 276.5, 
p = 0.212 
  Excited (P4, P7, G8, G14) 4.3 ± 0.6 5.1 ± 1.5   U = 209.5, 
p = 0.007 
  Depressed (G2, G3, G6) 5.5 ± 1.6 5.1 ± 2.2   U = 274, 
p = 0.237 
  Total PANSS score  40.0 ± 5.6 49.4 ± 11.2   t = 3.906 
p < 0.001 
HAMD 21 total score 4.7 ± 4.2 2.0 ± 4.2   U = 157.5, 
p < 0.0001 
CDSS total score 3.4 ± 3.0 1.6 ± 2.2   U = 204, 
p = 0.012 
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GAF score 64.8 ± 12.1 56.9 ± 9.6   t = -2.613, 
p = 0.012 
PSP total score 63.9 ± 14.4 56.4 ± 9.9   t = -2.163, 
p = 0.036 
Cognition 
     
Composite Cognitive Ability -0.256 ± 0.8 -0.616 ± 0.9 0 ± 0.5 t = 1.262, 
p = 0.215 
t = -1.452, 
p = 0.153 
MWT IQ 27.6 ± 3.9 25.9 ± 5.8 27.6 ± 4.0 t = 0.030,  
p = 0.976 
t = -1.155, 
p = 0.254 
Table 1. Summary of the socio-demographic and neuropsychological characteristics of the study participants. Data are presented as 
average ± standard deviation. Abbreviations: BD-I: Bipolar Disorder I; SZ: Schizophrenia; HC: Healthy controls; BNSS: Brief Negative 
Symptom Scale. BNSS Apathy was defined based on the BNSS subscales anhedonia (items 1-3), asociality (items 5, 6) and avolition 
(items 7, 8) and BNSS Diminished expression was defined as the sum of the BNSS subscales blunted affect (items 9-11) and alogia (items 
12, 13); PANSS: Positive and Negative Syndrome Scale; HAMD: Hamilton Depression Rating Scale; CDSS: Calgary Depression Scale for 
Schizophrenia; GAF: Global Assessment of Functioning; PSP: Personal and Social Performance Scale. MWT IQ: Multiple Word Test 
Intelligence Quotient. 
1
Group differences were investigated using 2-sample t tests for continuous and χ
2
 tests for categorical data. For 
non-normally distributed data Mann–Whitney U tests were applied. 
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Figure 1. 
(A) Comparison of BNSS apathy between BD-I patients and patients with schizophrenia revealed no 
differences whereas (B) BD-I patients showed lower BNSS Expression and (C) higher CDSS total scores 
than patients with schizophrenia. There was a significant correlation between BNSS apathy and CDSS 
in (D) BD-I but not in (E) patients with schizophrenia. * = p < 0.05 
 
Figure 2.  
Activation map of the reward anticipation contrast (anticipation of high reward vs. anticipation of no 
reward) across the complete sample. Illustrated in coronal orientation (upper line) and axial (lower 
line) orientation. The VS ROI (A) and DS ROI (B) were overlaid on the activation map. The threshold 
was set at P<.05 FWE corrected. 
 
 
Figure 3.  
(A, D) Group comparison of activation during reward anticipation revealed no differences between 
HC and individuals with BD-I in VS (A) or DS (D). (B, C) VS activity during reward anticipation did not 
correlate with apathy or diminished expression. (E, F) DS activity during reward anticipation did not 
correlate with apathy or diminished expression. 
 
Figure 4.  
Associations between apathy and reduced activation in the right inferior frontal gyrus (56, 27, 9, 
cluster size = 41, t = 5.05, p=.034, peak-level FWE <0.05 corrected) in euthymic BD-I patients.  
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